作者: originality 時(shí)間: 2025-3-21 23:50 作者: noxious 時(shí)間: 2025-3-22 02:14
Upstream Therapy in the Treatment of Atrial Fibrillation,at the blockers of the renin-angiotensin-aldosteron system, the statins and the polyunsaturated fatty acids might prevent atrial remodelling and thus atrial fibrillation, being called upstream therapy. However, later large and valid studies did not confirm the efficacy of this upstream therapy.作者: 樂意 時(shí)間: 2025-3-22 06:17 作者: GUILT 時(shí)間: 2025-3-22 10:52
,Jacobi’s Elliptical Functions,and perpetuation helps to change the management paradigm and to understand better the targets of the future therapy aimed to restore and maintain the sinus rhythm with the expected long-term consequences on outcome.作者: 配置 時(shí)間: 2025-3-22 14:04
Epidemiology, Burden and Unmet Needs in Atrial Fibrillation,ealth care managers because its medical, social and economic impact probably will worsen over the next decades. Therefore, research and future knowledge of AF will play a major role for modern societies.作者: 勾引 時(shí)間: 2025-3-22 19:38 作者: 不適當(dāng) 時(shí)間: 2025-3-22 21:16 作者: Chameleon 時(shí)間: 2025-3-23 03:05
Book 2014 how it can be applied with optimal efficacy. This book assists trainees, recertifying physicians, practicing physicians and other professional staff in internal medicine, cardiology, emergency medicine, and clinical pharmacology to apply new diagnostic tools for selecting the best treatment options for AF patients..作者: 貧窮地活 時(shí)間: 2025-3-23 05:57 作者: intercede 時(shí)間: 2025-3-23 10:34 作者: 粗語 時(shí)間: 2025-3-23 15:46
Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation, anticoagulation requires multiple blood tests and is very often hard to achieve, leading to suboptimal balance between thrombosis and bleeding. Novel Oral Anticoagulants (NOACs) were developed to overcome these limitations [3, 4]. The NOACs are divided into two classes: the oral direct thrombin inh作者: grounded 時(shí)間: 2025-3-23 20:20 作者: wall-stress 時(shí)間: 2025-3-24 01:45
Werte von , für jede ganze Zahl n anticoagulation requires multiple blood tests and is very often hard to achieve, leading to suboptimal balance between thrombosis and bleeding. Novel Oral Anticoagulants (NOACs) were developed to overcome these limitations [3, 4]. The NOACs are divided into two classes: the oral direct thrombin inh作者: Coeval 時(shí)間: 2025-3-24 05:58 作者: 條街道往前推 時(shí)間: 2025-3-24 08:52 作者: Vo2-Max 時(shí)間: 2025-3-24 14:36 作者: 絕緣 時(shí)間: 2025-3-24 18:36
Atrial Fibrillation Therapy978-1-4471-5475-4Series ISSN 2946-8183 Series E-ISSN 2946-8191 作者: Lobotomy 時(shí)間: 2025-3-24 21:12 作者: Synovial-Fluid 時(shí)間: 2025-3-25 01:26 作者: 值得尊敬 時(shí)間: 2025-3-25 04:33
978-1-4471-5474-7Springer-Verlag London 2014作者: 虛構(gòu)的東西 時(shí)間: 2025-3-25 10:30
,Abkürzungen und Kurzdefinitionen,on and contraction. Thus, the organized contractile capacity of the atrium for filling the ventricles is lost which diminishes the ventricular ejection, as well as, auricular blood stasis and turbulent flow favors thrombosis and consequent thromboembolism may develop. Therefore, this arrhythmia has 作者: 過分 時(shí)間: 2025-3-25 15:35 作者: BACLE 時(shí)間: 2025-3-25 17:34
Werte von , für jede ganze Zahl nn patients with AF is associated with higher mortality, severe disability and high recurrence rate. Antithrombotic therapy is effective to prevent stroke in AF patients. Vitamin K Antagonists (VKA) are much more effective than aspirin and, in the absence of contraindication, are highly recommended f作者: 欲望 時(shí)間: 2025-3-25 21:33 作者: 他一致 時(shí)間: 2025-3-26 01:05 作者: Diatribe 時(shí)間: 2025-3-26 08:02
,Jacobi’s Elliptical Functions,rovement in our knowledge about the mechanisms involved in the initiation and perpetuation of AF the therapy is still challenging. The current statement of the clinical equivalence between rate control and rhythm control strategy is biased by the efficacy and safety limitations of the current antiar作者: BOOR 時(shí)間: 2025-3-26 11:50
Gheorghe-Andrei Dan,Antoni Bayés de Luna,John CammDiscusses new diagnostic tools for best selecting AF patients for specific therapies.Presents recent research in a highly practical, easy reference style.Emphasis is on a just-the-facts approach to th作者: neutralize 時(shí)間: 2025-3-26 12:40 作者: Detain 時(shí)間: 2025-3-26 20:13
Epidemiology, Burden and Unmet Needs in Atrial Fibrillation,on and contraction. Thus, the organized contractile capacity of the atrium for filling the ventricles is lost which diminishes the ventricular ejection, as well as, auricular blood stasis and turbulent flow favors thrombosis and consequent thromboembolism may develop. Therefore, this arrhythmia has 作者: ATRIA 時(shí)間: 2025-3-26 21:07 作者: 細(xì)絲 時(shí)間: 2025-3-27 02:26 作者: innovation 時(shí)間: 2025-3-27 07:38 作者: Abbreviate 時(shí)間: 2025-3-27 11:21
Drug Therapy for Rhythm and Rate Control in Atrial Fibrillation,ignificant increase in mortality and morbidity. Thus, being AF a potentially dangerous arrhythmia, it seems logical to use antiarrhythmic strategies to avoid, or at least control, this rhythm disturbance [1, 2].作者: mechanism 時(shí)間: 2025-3-27 14:10
Changing the Paradigm to Understand and Manage Atrial Fibrillation,rovement in our knowledge about the mechanisms involved in the initiation and perpetuation of AF the therapy is still challenging. The current statement of the clinical equivalence between rate control and rhythm control strategy is biased by the efficacy and safety limitations of the current antiar作者: Self-Help-Group 時(shí)間: 2025-3-27 18:16
9樓作者: adduction 時(shí)間: 2025-3-27 23:40
10樓作者: 冷峻 時(shí)間: 2025-3-28 04:07
10樓作者: 色情 時(shí)間: 2025-3-28 08:30
10樓作者: 顛簸下上 時(shí)間: 2025-3-28 14:15
10樓
